CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CCND1 expression
|
NSCLC
|
CCND1 expression
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
CCND1 expression
|
Mantle Cell Lymphoma
|
CCND1 expression
|
Mantle Cell Lymphoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
CCND1 expression
|
Multiple Myeloma
|
CCND1 expression
|
Multiple Myeloma
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|